Clinical trials: Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT01283971
- Testing
- tocilizumab [RoActemra/Actemra], adalimumab, methotrexate
- Where
- 170 sites in United States, Denmark and 10 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who…
- Trial name
- NCT03813199
- Testing
- ABX464 50mg, ABX464 100mg, Methotrexate
- Where
- 24 sites in Belgium, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.
- Trial name
- NCT01347983
- Testing
- Tocilizumab+Methotrexate(MTX)
- Where
- 12 sites in Taiwan
- Volunteers
- 72 people
- Sponsor
- Chugai Pharma Taiwan
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core…
- Trial name
- NCT01662063
- Testing
- Tocilizumab
- Where
- 79 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis
This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to severe Rheumatoid Arthritis for a period of 52 weeks.
- Trial name
- NCT01612377
- Testing
- Prednisolone-Dipyridamole, Prednisone
- Where
- Serbia
- Volunteers
- 18 people
- Sponsor
- Zalicus
Rheumatoid Arthritis
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)
This observational study will evaluate the long-term efficacy and safety of RoActemra/Actemra (tocilizumab in participants of the ACT SURE clinical trial and further patients with moderate to severe rheumatoid arthritis starting…
- Trial name
- NCT01483326
- Where
- 19 sites in Netherlands
- Volunteers
- 215 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
This was a Phase II, randomized, double-blind, multicenter study designed to evaluate the safety and efficacy of rituximab, administered at two different regimens for 2 years, in patients with moderate to severe active rheumatoid…
- Trial name
- RUMBA (NCT00243412)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 42 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Primary Objective: -To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.
- Trial name
- NCT02293902
- Testing
- Sarilumab SAR153191 (REGN88), Methotrexate, Folic acid
- Where
- 96 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Sanofi
Rheumatoid Arthritis, Arthritis, Rheumatoid
A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis
This is a multicentre, randomised, double-blind, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, safety, tolerability and efficacy of JHL1101 versus MabThera in subjects with…
- Trial name
- NCT03161457
- Testing
- JHL1101, MabThera
- Where
- 32 sites in Bosnia and Herzegovina, Bulgaria and 9 more
- Volunteers
- 153 people
- Sponsor
- JHL Biotech, Inc.
Rheumatoid Arthritis
Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD
This is a multicenter, randomized, double-blind, parallel, placebo- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD…
- Trial name
- NCT07423533
- Testing
- GenSci120 150 mg, GenSci120 600 mg, GenSci120 1000 mg
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.
The goal of this multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial is to evaluate the efficacy and safety of proximod in active rheumatoid arthritis patients with inadequate response or intolerance…
- Trial name
- PROXIMA (NCT07335952)
- Testing
- proximod 5mg daily, proximod 10mg daily
- Where
- 20 sites in China
- Volunteers
- 179 people
- Sponsor
- Peking University People's Hospital
Rheumatoid Arthritis
A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
The purpose of this study is to assess the efficacy and safety of dose regimens of ALX-0061 administered subcutaneously (s.c.) in combination with methotrexate (MTX) to subjects with active rheumatoid arthritis (RA) despite MTX…
- Trial name
- NCT02309359
- Testing
- ALX-0061, Methotrexate
- Where
- 94 sites in United States, Belgium and 12 more
- Volunteers
- 345 people
- Sponsor
- Ablynx, a Sanofi company
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Moderate to Severe Active Rheumatoid Arthritis
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
- Trial name
- NCT07233655
- Testing
- SHR-3045 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Rheumatoid Arthritis, Arthritis
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
- Conditions
- Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases
- Trial name
- RESOLUTION-1 (NCT05516758)
- Testing
- Peresolimab
- Where
- 131 sites in United States, Argentina and 9 more
- Volunteers
- 491 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe…
- Trial name
- NCT01500278
- Testing
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Where
- 175 sites in United States, Australia and 18 more
- Volunteers
- 915 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients
The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.
- Trial name
- PICS (NCT01213017)
- Testing
- certolizumab pegol
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Oklahoma Medical Research Foundation
Rheumatoid Arthritis
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
CMAB008 is an infliximab biosimilar candidate. The host cell of Remicade is mouse myeloma SP2/0 cell, however, the host cell of CMAB008 is CHO (Chinese hamster ovary cell).
- Trial name
- NCT03478111
- Testing
- CMAB008, MTX, Remicade
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate.
- Trial name
- FLEX M (NCT01198002)
- Testing
- LY2127399, Methotrexate
- Where
- 234 sites in United States, Argentina and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Eli Lilly and Company